Research overview: SDMA as an early biomarker of feline kidney disease

Symmetric dimethylarginine (SDMA) emerged as a blood biomarker of kidney function that rises earlier in the course of feline CKD than creatinine and is less influenced by muscle mass, an advantage in older, often muscle-wasted cats. Its adoption into routine panels and IRIS staging allowed earlier detection and intervention. This overview compiles the biomarker literature rather than one source, describing how SDMA reflects glomerular filtration, why it can flag declining kidney function before creatinine crosses reference limits, and the ongoing discussion about its specificity and best use. It matters because earlier detection creates opportunities for dietary and medical management that may slow progression of a disease that is a leading cause of death in senior cats.